CN Patent

CN116987070B — 呋喹替尼的共晶、其制备方法、组合物和用途

Assigned to Hangzhou Lingye Pharmaceutical Technology Co ltd · Expires 2026-02-06 · 0y expired

What this patent protects

本发明涉及新型的呋喹替尼与对离子形成的化合物，与呋喹替尼的现有技术相比，所述化合物具有一种或多种改进的特性。本发明还涉及所述化合物的制备方法，其药物组合物及其用于制备治疗和/或预防与患者血管生成异常相关疾病如癌症、肿瘤、黄斑性病变和慢性炎症等的药物中的用途。

USPTO Abstract

本发明涉及新型的呋喹替尼与对离子形成的化合物，与呋喹替尼的现有技术相比，所述化合物具有一种或多种改进的特性。本发明还涉及所述化合物的制备方法，其药物组合物及其用于制备治疗和/或预防与患者血管生成异常相关疾病如癌症、肿瘤、黄斑性病变和慢性炎症等的药物中的用途。

Drugs covered by this patent

Patent Metadata

Patent number: CN116987070B
Jurisdiction: CN
Classification: —
Expires: 2026-02-06
Drug substance claim: No
Drug product claim: No
Assignee: Hangzhou Lingye Pharmaceutical Technology Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.